Solvar Extends On-Market Buy-Back Program for 12 Months

Renewal of Share Buy-Back Program

Solvar Limited (ASX:SVR) has secured board approval to renew its on-market share buy-back program for another 12 months, extending the initiative from 3 June 2026 through to 2 June 2027. This move underscores the company’s ongoing commitment to capital management and shareholder value optimisation.

The buy-back’s execution will hinge on several factors including the prevailing share price, market conditions, and Solvar’s forecast capital requirements. The company also flagged that unforeseen circumstances could influence the timing and volume of shares repurchased, with all transactions subject to regulatory compliance.

Capital Management in a Changing Market

This renewal comes after Solvar’s recent financial performance, which included a 5.8% rise in half-year net profit and the sale of its New Zealand loan book, as reported earlier this year. The company has been balancing growth with prudent capital returns, having previously deployed buy-backs alongside special dividends to reward shareholders.

Solvar’s strategy reflects a nuanced approach to capital allocation, especially following the resolution of regulatory challenges faced by its subsidiary Money3 Loans. The Federal Court imposed a $1.55 million penalty for past breaches, but Solvar has since emphasised strengthened governance and underwriting standards, aiming to restore investor confidence.

Implications for Investors and Market Watchers

Investors should note that while the buy-back program is authorised for another year, the actual scale and timing of share purchases remain uncertain. This flexibility allows Solvar to adapt to market fluctuations and capital demands, potentially cushioning the share price or enhancing earnings per share through reduced share count.

The company’s ongoing focus on capital efficiency will be closely watched, especially given its recent moves to exit the New Zealand market and expand funding facilities. The updated Appendix 3C detailing the buy-back parameters is expected to provide further clarity once released.

Solvar’s dual focus on operational growth and capital returns, in the wake of regulatory scrutiny and market repositioning, raises questions about how aggressively it will deploy the buy-back in the coming year and what that signals about its confidence in future earnings.